Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A partially grouped logrank test

R Sposto1, D Stablein, S Carter-Campbell

  • 1Children's Cancer Group, Arcadia, California, 91066-6012, USA.

Statistics in Medicine
|March 30, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation in pediatric patients with malignant brain tumors.

Bone marrow transplantation·2017
Same author

Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness.

Allergy·2016
Same author

A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy.

Allergy·2013
Same author

Liver transplant outcomes in HIV+ haemophilic men.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

British journal of cancer·2010
Same author

Central nervous system (CNS) tumors in the first six months of life: the Children's Hospital Los Angeles experience, 1979-2005.

Pediatric hematology and oncology·2010

This study introduces a modified logrank test for survival data, grouping early data to reduce bias from non-proportional hazards. This approach enhances interim monitoring for lagged treatment effects.

Area of Science:

  • Biostatistics
  • Survival Analysis
  • Clinical Trial Design

Background:

  • Standard logrank tests assume proportional hazards, which may not hold early in survival studies.
  • Non-proportional hazards can bias standard tests, especially with lagged treatment effects.
  • Interim monitoring requires robust statistical methods sensitive to delayed treatment efficacy.

Purpose of the Study:

  • To develop a modified logrank test robust to early non-proportional hazards.
  • To improve the reliability of interim analyses in clinical trials with potential lagged treatment effects.
  • To maintain high statistical efficiency comparable to the standard logrank test.

Main Methods:

  • A modified logrank test statistic is proposed, incorporating data grouping before a specified time point.

Related Experiment Videos

  • The initial grouping is based on product limit estimates of survival proportions at the grouping time.
  • Subsequent contributions to the statistic mirror the standard logrank test.

    • Main Results:

    • The modified test is less influenced by early non-proportional hazards differences.
    • It demonstrates high efficiency, approaching that of the standard logrank test for proportional hazards.
    • Simulation studies confirm the test's properties and utility.

    Conclusions:

    • The modified logrank test offers a valuable tool for interim monitoring in survival data analysis.
    • It is particularly advantageous when early treatment differences are minimal or effects are delayed.
    • This method enhances the accuracy of survival data interpretation during clinical trials.